|
| 37641451 | Neuropil-like islands are a possible pathogenetic link between glioblastoma and gangliocytoma/ganglioglioma in a case of synchronous bilateral brain tumors. | Neuropathology | 2024 |
| 36334050 | Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. | Neuro Oncol | 2023 |
| 37749662 | Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study. | Acta Neuropathol Commun | 2023 |
| 37900802 | Miliary Tuberculosis during R-MPV Therapy in an Elderly Patient with Primary Central Nerve System Lymphoma: A Case Report. | Case Rep Oncol | 2023 |
| 37744697 | Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib. | Neurooncol Adv | 2023 |
| 37735187 | Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors. | Sci Rep | 2023 |
| 35722822 | The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. | Neuro Oncol | 2023 |
| 37322295 | A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment. | Brain Tumor Pathol | 2023 |
| 36995447 | Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. | Brain Tumor Pathol | 2023 |
| 36647599 | Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. | Jpn J Clin Oncol | 2023 |
| 36745216 | Clinical significance and pitfalls of human chorionic gonadotropin-related tumor markers for intracranial germinomas. | Childs Nerv Syst | 2023 |
| 34608699 | Cytopathological and histopathological features of cerebral granular cell astrocytoma: A case report. | Cytopathology | 2022 |
| 35842871 | Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. | J Neurooncol | 2022 |
| 35611272 | Still divergent but on the way to convergence: clinical practice of CNS germ cell tumors in Europe and North America from the perspectives of the East. | Neurooncol Adv | 2022 |
| 36469605 | A case of aggressive pituitary neuroendocrine tumour with extremely rapid progression: possible diagnostic value of <i>TERT</i> promoter methylation. | Br J Neurosurg | 2022 |
| 36428615 | Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. | Cancers (Basel) | 2022 |
| 36046704 | True anaplastic oligoastrocytoma with dual genotype: illustrative case. | J Neurosurg Case Lessons | 2022 |
| 35918310 | A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors. | Nat Commun | 2022 |
| 35098127 | Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial. | Neurooncol Adv | 2022 |
| 35000018 | Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors. | Brain Tumor Pathol | 2022 |
| 35205726 | Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort. | Cancers (Basel) | 2022 |
| 34671804 | The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. | Neuro Oncol | 2022 |
| 34698864 | 12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. | Neuro Oncol | 2022 |
| 32583848 | Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. | Neuro Oncol | 2021 |
| 35582067 | A case of torsades de pointes due to takotsubo cardiomyopathy after common atrial flutter ablation. | J Cardiol Cases | 2021 |
| 33649776 | Exosome-mediated radiosensitizing effect on neighboring cancer cells via increase in intracellular levels of reactive oxygen species. | Oncol Rep | 2021 |
| 33539787 | PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. | Mol Cell | 2021 |
| 33917660 | Tumor-Treating Fields Therapy for Pediatric Brain Tumors. | Neurol Int | 2021 |
| 33808802 | Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. | Cancers (Basel) | 2021 |
| 33913040 | Unique pathological findings of astroblastoma with MN1 alteration in a patient with late recurrence. | Brain Tumor Pathol | 2021 |
| 34765975 | Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial. | Neurooncol Adv | 2021 |
| 34586548 | Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. | Int J Clin Oncol | 2021 |
| 34406623 | Determining the extent of tumor resection at surgical planning with <sup>18</sup>F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials. | Ann Nucl Med | 2021 |
| 34732592 | The Japan Neurosurgical Database: Statistics Update 2018 and 2019. | Neurol Med Chir (Tokyo) | 2021 |
| 34549182 | Low tumor cell content predicts favorable prognosis in germinoma patients. | Neurooncol Adv | 2021 |
| 34654402 | A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). | BMC Cancer | 2021 |
| 34272633 | Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. | J Neurooncol | 2021 |
| 34128111 | Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. | Brain Tumor Pathol | 2021 |
| 34148105 | TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. | Acta Neuropathol | 2021 |
| 34092748 | Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan. | Neurol Med Chir (Tokyo) | 2021 |
| 34092558 | [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors]. | No Shinkei Geka | 2021 |
| 34355172 | Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging-A controversy. | Neurooncol Adv | 2021 |
| 32818237 | So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma? | Neuro Oncol | 2021 |
| 32367437 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. | J Neurooncol | 2020 |
| 32005022 | Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts. | J Neurosurg | 2020 |
| 33228806 | TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. | Acta Neuropathol Commun | 2020 |
| 33051400 | [Glioblastoma Mimicking Meningioma Recurrence: A Case Report]. | Brain Nerve | 2020 |
| 32632894 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. | J Neurooncol | 2020 |
| 32238620 | The Japan Neurosurgical Database: Overview and Results of the First-year Survey. | Neurol Med Chir (Tokyo) | 2020 |
| 30500939 | A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. | Neuro Oncol | 2019 |